The rise of e-cigarette usage has provoked vigorous debate within the public health community and among health care providers, despite the common goal of getting patients to be completely smoke and vape free.
New recommendations will include a large guideline update on the use of systemic treatment for patients with stage IV non–small cell lung cancer and cover the rapidly advancing area of molecular testing for patients with either early-stage or advanced lung cancer.
Results from the phase III IFCT-GFPC-0701 MAPS trial found that the addition of bevacizumab to standard chemotherapy in patients with malignant pleural mesothelioma prolonged overall survival by 2.75 months.
The high-affinity, humanized monoclonal PD-1 antibody pembrolizumab showed promising antitumor activity in heavily pretreated, PD-L1-positive patients with extensive-stage small cell lung cancer in the KEYNOTE-028 trial.
In patients with advanced nsNSCLC, a chemotherapy regimen including pemetrexed had a better safety profile than one including etoposide, but demonstrated no improvement in survival outcomes. Routine use of the regimen may be questionable, given its considerably higher cost.